Pfizer reaches deal with Trump admin on drug pricing
Pfizer rose Tuesday after it was announced that the drugmaker reached a deal with the Trump administration to lower its prices in the US.
Pfizer will sell its drugs through Medicaid at lower prices, according to the White House. In its own press release, Pfizer said it has agreed to take steps to ensure Americans receive “comparable drug prices to those available in other developed countries” and will price “newly launched medicines at parity with other key developed markets.”
Pfizer said it would participate in the administration’s direct-to-consumer platform dubbed “TrumpRx.” Many of the company’s drugs will be available on TrumpRx.gov (the website does not appear to be active yet) at “at savings that will range as high as 85% and on average 50%.”
The specific terms of the agreement are confidential, Pfizer said. President Trump signed an executive order in May demanding drugmakers give the US the best prices on medications, and the deadline to comply with that was Monday.